Qiujun Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qiujun Guo has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Wei Hou
Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
7 shared publications- Baojin Hua
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, No. 5 Beixiange, Xicheng District, Beijing 100053, China
5 shared publications - Baojin Hua
Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
5 shared publications - Yuan Yuan
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, No. 5 Beixiange, Xicheng District, Beijing 100053, China; Beijing University of Chinese Medicine, No. 11 North Third Ring Road East, Chaoyang District, Beijing 100029, China
5 shared publications - Conghuang Li
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, No. 5 Beixiange, Xicheng District, Beijing 100053, China
4 shared publications - Huamin Wei
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, No. 5 Beixiange, Xicheng District, Beijing 100053, China
4 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Elsevier in Brain Research Bulletin
- Vol. 245
An intracranial small cell lung cancer inoculation model in BALB/c-nu mice reveals tumor-associated neuroinflammation and synaptic injury
- 3 September 2026
- Published by Elsevier in Brain Research Bulletin
- Vol. 245
Open AccessAn intracranial small cell lung cancer inoculation model in BALB/c-nu mice reveals tumor-associated neuroinflammation and synaptic injury
- Open Access
- 11 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1931069
Multifaceted mechanisms of unconventional T cells in ischemia-reperfusion injury
Ischemia-reperfusion injury (IRI) constitutes a common pathological basis for organ dysfunction across various critical clinical conditions, including ischemic stroke, myocardial infarction, and organ transplantation. This review focuses on the functions of unconventional T cells in IRI in the brain, liver, kidneys, heart, and mucosal barrier organs, highlighting their diverse regulatory mechanisms in various tissue injury patterns. It also examines the dual functions of these cells in IRI: instead of solely acting as consistent pro-inflammatory effectors, they demonstrate a context-dependent immunomodulatory profile influenced by the organ microenvironment and disease stage, capable of promoting inflammatory damage and facilitating anti-inflammatory repair. Their behavior is shaped by a common injury response program that integrates local antigen cues, the cytokine milieu, metabolic checkpoints, and signals from the repair stage. Expounding on the spatiotemporal heterogeneity, functional plasticity, and regulatory networks of unconventional T cells in IRI will enhance our understanding of the immunopathological mechanisms. It also offers a theoretical basis and potential targets for formulating precision immunomodulatory strategies tailored to specific time windows and cell subsets.
- 11 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1931069
Open AccessMultifaceted mechanisms of unconventional T cells in ischemia-reperfusion injury
Ischemia-reperfusion injury (IRI) constitutes a common pathological basis for organ dysfunction across various critical clinical conditions, including ischemic stroke, myocardial infarction, and organ transplantation. This review focuses on the functions of unconventional T cells in IRI in the brain, liver, kidneys, heart, and mucosal barrier organs, highlighting their diverse regulatory mechanisms in various tissue injury patterns. It also examines the dual functions of these cells in IRI: instead of solely acting as consistent pro-inflammatory effectors, they demonstrate a context-dependent immunomodulatory profile influenced by the organ microenvironment and disease stage, capable of promoting inflammatory damage and facilitating anti-inflammatory repair. Their behavior is shaped by a common injury response program that integrates local antigen cues, the cytokine milieu, metabolic checkpoints, and signals from the repair stage. Expounding on the spatiotemporal heterogeneity, functional plasticity, and regulatory networks of unconventional T cells in IRI will enhance our understanding of the immunopathological mechanisms. It also offers a theoretical basis and potential targets for formulating precision immunomodulatory strategies tailored to specific time windows and cell subsets.
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 5626229
Shuangshen Granule Regulates Tumor Cell Exosomes Through MIF‐miR‐34a‐KLF4 Pathway and Affects Macrophage Polarization Against Lung Cancer
The incidence and mortality of lung cancer are among the highest in the world, involving a variety of complex pathological mechanisms and processes. Previous studies have demonstrated that the tumor immunosuppressive microenvironment (TIME) plays a key role in tumor progression, promoting tumor invasion and metastasis and leading to resistance to therapy. Tumor‐associated macrophages (TAMs) are important cell components in TIME, and their phenotypes affect the prognosis of tumors. Tumor‐derived exosomes carrying specific information as a medium of crosstalk between macrophages and tumor cells are considered to be an underexplored information transfer medium affecting tumor progression and tumor microenvironment remodeling. In the previous study, we found that Shuangshen granule (SSG) can reduce the formation of lung tumors in mouse models of spontaneous lung cancer, but the specific mechanism of SSG inhibiting lung cancer has not been solved. Starting from the exosomes of tumor cells, we established the M1‐like TAMs overexpression mouse lung cancer transplantation tumor model and constructed MIF +/+ Lewis stable transfection cell line and shMIF Lewis stable transfection cell line to analyze the specific molecular biological mechanism of SSG inhibiting lung cancer. The experimental results showed that SSG significantly reduced the volume and mass of Lewis lung cancer xenografts in mice, and its inhibitory effect on Lewis lung cancer was related to the increase in the proportion of M1‐like TAMs. Flow cytometry and western blot revealed that SSG can increase the proportion of CD8 + central memory T cells, reduce the proportion of CD8 + effector memory T cells, reduce the proportion of CD4 + CD25 + Foxp3 + Treg cells, and play a role in regulating the tumor microenvironment. In vitro experiments further showed that SSG drug–containing serum could inhibit the expression of MIF protein and RNA in MIF +/+ Lewis cells and increase the expression of miR‐34a in MIF +/+ Lewis cell exosomes. Interestingly, we also found that MIF +/+ Lewis cell–derived exosomes after SSG‐containing serum intervention can reverse the increase in the proportion of M2‐like TAMs and increase the proportion of M1‐like TAMs. Subsequent gene modification experiments showed that MIF +/+ Lewis cell exosomes can increase the expression of the KLF4 gene in macrophages in vitro. In conclusion, our study revealed that SSG can regulate the polarization of TAMs through lung cancer cell–derived exosomes, and its mechanism is related to the MIF‐miR‐34a‐KLF4 pathway. Summary: SSG can inhibit the proliferation of lung cancer, which is related to the antitumor mechanism involving macrophages. The poor prognosis of lung cancer caused by macrophage migration inhibitory factor (MIF) is related to the TAM phenotype, and SSG can inhibit lung cancer by inhibiting MIF. SSG regulates the tumor cell MIF‐MiR‐34a exosome pathway and regulates the polarization and function of TAMs.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 5626229
Open AccessShuangshen Granule Regulates Tumor Cell Exosomes Through MIF‐miR‐34a‐KLF4 Pathway and Affects Macrophage Polarization Against Lung Cancer
The incidence and mortality of lung cancer are among the highest in the world, involving a variety of complex pathological mechanisms and processes. Previous studies have demonstrated that the tumor immunosuppressive microenvironment (TIME) plays a key role in tumor progression, promoting tumor invasion and metastasis and leading to resistance to therapy. Tumor‐associated macrophages (TAMs) are important cell components in TIME, and their phenotypes affect the prognosis of tumors. Tumor‐derived exosomes carrying specific information as a medium of crosstalk between macrophages and tumor cells are considered to be an underexplored information transfer medium affecting tumor progression and tumor microenvironment remodeling. In the previous study, we found that Shuangshen granule (SSG) can reduce the formation of lung tumors in mouse models of spontaneous lung cancer, but the specific mechanism of SSG inhibiting lung cancer has not been solved. Starting from the exosomes of tumor cells, we established the M1‐like TAMs overexpression mouse lung cancer transplantation tumor model and constructed MIF +/+ Lewis stable transfection cell line and shMIF Lewis stable transfection cell line to analyze the specific molecular biological mechanism of SSG inhibiting lung cancer. The experimental results showed that SSG significantly reduced the volume and mass of Lewis lung cancer xenografts in mice, and its inhibitory effect on Lewis lung cancer was related to the increase in the proportion of M1‐like TAMs. Flow cytometry and western blot revealed that SSG can increase the proportion of CD8 + central memory T cells, reduce the proportion of CD8 + effector memory T cells, reduce the proportion of CD4 + CD25 + Foxp3 + Treg cells, and play a role in regulating the tumor microenvironment. In vitro experiments further showed that SSG drug–containing serum could inhibit the expression of MIF protein and RNA in MIF +/+ Lewis cells and increase the expression of miR‐34a in MIF +/+ Lewis cell exosomes. Interestingly, we also found that MIF +/+ Lewis cell–derived exosomes after SSG‐containing serum intervention can reverse the increase in the proportion of M2‐like TAMs and increase the proportion of M1‐like TAMs. Subsequent gene modification experiments showed that MIF +/+ Lewis cell exosomes can increase the expression of the KLF4 gene in macrophages in vitro. In conclusion, our study revealed that SSG can regulate the polarization of TAMs through lung cancer cell–derived exosomes, and its mechanism is related to the MIF‐miR‐34a‐KLF4 pathway. Summary: SSG can inhibit the proliferation of lung cancer, which is related to the antitumor mechanism involving macrophages. The poor prognosis of lung cancer caused by macrophage migration inhibitory factor (MIF) is related to the TAM phenotype, and SSG can inhibit lung cancer by inhibiting MIF. SSG regulates the tumor cell MIF‐MiR‐34a exosome pathway and regulates the polarization and function of TAMs.
- Open Access
- 12 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (37) , e41820
Bidirectional Mendelian randomization and immune cell mediation analysis: A STROBE-MR study unveiling the causal link between non-small cell and small cell lung cancers
A certain number of non-small cell lung cancer (NSCLC) transform into small cell lung cancer (SCLC) during treatment, presenting a poorer prognosis compared to the original tumor. However, the causal association between NSCLC and SCLC remains uncertain. We utilized Mendelian randomization (MR) and colocalization analysis to investigate potential causal relationships between NSCLC and SCLC. Additionally, we employed mediation analysis to assess the mediating effect of immune cells on the causal relationship between squamous cell carcinoma (LUSC) and SCLC. Summary data on lung cancer subtypes and immune cells were obtained from comprehensive genetic databases FinnGen, TRICL and GWAS catalog. Our findings suggest a strong causal relationship between NSCLC and SCLC (OR = 2.20, 95% CI = 1.32–3.69, P -value < .01), specifically between LUSC and SCLC (OR = 1.98, 95% CI = 1.23–3.19, P -value < .01). Mediation analysis showed that LUSC had a causal effect on 26 subsets of immune cells, while CD25 on IgD − CD38 − B cell had a reverse causal relationship with SCLC (OR = 0.732, 95% CI = 0.602–0.891, P = .002). Colocalization and annotation analysis highlighted BRCA2, CYP2A6, and CHRNA3 as shared causal genes of LUSC on SCLC. This genetic association study provided evidence of a causal relationship between NSCLC (specifically LUSC) and SCLC, emphasizing the importance of genetic factors and the need for routine genetic profiling in clinical practice, while also highlighting the necessity for further research to understand the underlying mechanisms for developing more effective therapies.
- 12 September 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (37) , e41820
Open AccessBidirectional Mendelian randomization and immune cell mediation analysis: A STROBE-MR study unveiling the causal link between non-small cell and small cell lung cancers
A certain number of non-small cell lung cancer (NSCLC) transform into small cell lung cancer (SCLC) during treatment, presenting a poorer prognosis compared to the original tumor. However, the causal association between NSCLC and SCLC remains uncertain. We utilized Mendelian randomization (MR) and colocalization analysis to investigate potential causal relationships between NSCLC and SCLC. Additionally, we employed mediation analysis to assess the mediating effect of immune cells on the causal relationship between squamous cell carcinoma (LUSC) and SCLC. Summary data on lung cancer subtypes and immune cells were obtained from comprehensive genetic databases FinnGen, TRICL and GWAS catalog. Our findings suggest a strong causal relationship between NSCLC and SCLC (OR = 2.20, 95% CI = 1.32–3.69, P -value < .01), specifically between LUSC and SCLC (OR = 1.98, 95% CI = 1.23–3.19, P -value < .01). Mediation analysis showed that LUSC had a causal effect on 26 subsets of immune cells, while CD25 on IgD − CD38 − B cell had a reverse causal relationship with SCLC (OR = 0.732, 95% CI = 0.602–0.891, P = .002). Colocalization and annotation analysis highlighted BRCA2, CYP2A6, and CHRNA3 as shared causal genes of LUSC on SCLC. This genetic association study provided evidence of a causal relationship between NSCLC (specifically LUSC) and SCLC, emphasizing the importance of genetic factors and the need for routine genetic profiling in clinical practice, while also highlighting the necessity for further research to understand the underlying mechanisms for developing more effective therapies.
- Open Access
- 27 January 2025
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 14 (1) , 1-47
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics
Telomeres and telomerase play crucial roles in the initiation and progression of cancer. As biomarkers, they aid in distinguishing benign from malignant tissues. Despite the promising therapeutic potential of targeting telomeres and telomerase for therapy, translating this concept from the laboratory to the clinic remains challenging. Many candidate drugs remain in the experimental stage, with only a few advancing to clinical trials. This review explores the relationship between telomeres, telomerase, and cancer, synthesizing their roles as biomarkers and reviewing the outcomes of completed trials. We propose that changes in telomere length and telomerase activity can be used to stratify cancer stages. Furthermore, we suggest that differential expression of telomere and telomerase components at the subcellular level holds promise as a biomarker. From a therapeutic standpoint, combining telomerase-targeted therapies with drugs that mitigate the adverse effects of telomerase inhibition may offer a viable strategy.
- 27 January 2025
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 14 (1) , 1-47
Open AccessTelomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics
Telomeres and telomerase play crucial roles in the initiation and progression of cancer. As biomarkers, they aid in distinguishing benign from malignant tissues. Despite the promising therapeutic potential of targeting telomeres and telomerase for therapy, translating this concept from the laboratory to the clinic remains challenging. Many candidate drugs remain in the experimental stage, with only a few advancing to clinical trials. This review explores the relationship between telomeres, telomerase, and cancer, synthesizing their roles as biomarkers and reviewing the outcomes of completed trials. We propose that changes in telomere length and telomerase activity can be used to stratify cancer stages. Furthermore, we suggest that differential expression of telomere and telomerase components at the subcellular level holds promise as a biomarker. From a therapeutic standpoint, combining telomerase-targeted therapies with drugs that mitigate the adverse effects of telomerase inhibition may offer a viable strategy.
- Open Access
- 28 December 2020
- Published by Springer Nature in Research Square
A Network Pharmacology Approach to Determine the Mechanisms of Action of Shuangshen Granules in Suppressing Pancreatic Cancer Precursor Lesions
Background and purpose: Pancreatic cancer is an insidious and highly lethal disease. Recognition and treatment of pancreatic cancer precursor lesions (PCPL) are important measures and can improve patient survival rate. Shuangshen Granules (SSG) have been prescribed for use in clinical practice for more than seven years and are widely used to treat the precursor lesions of various tumours. In this study, we used network pharmacology to explore the pharmacological mechanisms through which SSG suppress PCPL. We aimed to provide a basis for further research and the development of small, molecular, natural chemical drugs.Methods: We first searched databases and screened the bioactive components of SSG and the related targets acting on PCPL to construct a component-target network. Then, network topology analysis was used to analyse the hub target of SSG acting on PCPL. Enrichment analyses of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were also performed to determine the potential pathways. Finally, molecular docking simulations were carried out to investigate the interactions between PCPL-target proteins and the active components of SSG.Results: Seven of the main components of SSG affected PCPL, with 100 key targets including 16 hub targets. In addition, GO and KEGG enrichment analysis revealed that SSG regulated 111 molecular functions, 46 cellular components, 2334 biological processes, and 144 related signalling pathways, of which 26 were closely related to PCPL. Results of molecular docking analysis showed that the PCPL-related targets had strong binding properties with the active components of SSG, quercetin, and ginsenoside rh2, mainly TNF, IL-6, AKT1, TP53, and EGFR.Conclusion: This study has revealed the pharmacological and molecular mechanisms through which SSG acts on PCPL. It also provides powerful evidence to support the exploration of the pharmacological mechanisms of action and clinical applications of traditional Chinese medicine.
- 28 December 2020
- Published by Springer Nature in Research Square
Open AccessA Network Pharmacology Approach to Determine the Mechanisms of Action of Shuangshen Granules in Suppressing Pancreatic Cancer Precursor Lesions
Background and purpose: Pancreatic cancer is an insidious and highly lethal disease. Recognition and treatment of pancreatic cancer precursor lesions (PCPL) are important measures and can improve patient survival rate. Shuangshen Granules (SSG) have been prescribed for use in clinical practice for more than seven years and are widely used to treat the precursor lesions of various tumours. In this study, we used network pharmacology to explore the pharmacological mechanisms through which SSG suppress PCPL. We aimed to provide a basis for further research and the development of small, molecular, natural chemical drugs.Methods: We first searched databases and screened the bioactive components of SSG and the related targets acting on PCPL to construct a component-target network. Then, network topology analysis was used to analyse the hub target of SSG acting on PCPL. Enrichment analyses of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were also performed to determine the potential pathways. Finally, molecular docking simulations were carried out to investigate the interactions between PCPL-target proteins and the active components of SSG.Results: Seven of the main components of SSG affected PCPL, with 100 key targets including 16 hub targets. In addition, GO and KEGG enrichment analysis revealed that SSG regulated 111 molecular functions, 46 cellular components, 2334 biological processes, and 144 related signalling pathways, of which 26 were closely related to PCPL. Results of molecular docking analysis showed that the PCPL-related targets had strong binding properties with the active components of SSG, quercetin, and ginsenoside rh2, mainly TNF, IL-6, AKT1, TP53, and EGFR.Conclusion: This study has revealed the pharmacological and molecular mechanisms through which SSG acts on PCPL. It also provides powerful evidence to support the exploration of the pharmacological mechanisms of action and clinical applications of traditional Chinese medicine.
- Open Access
- 17 September 2020
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 12 (e6) , e1-e13
Breast cancer prognosis and P-cadherin expression: systematic review and study-level meta-analysis
Objective: P-cadherin can act both as a tumour suppressor and an oncogene. The clinical prognostic value of P-cadherin overexpression in breast cancer (BC) remains unclear. We conducted a study-level meta-analysis to determine whether P-cadherin expression can help predict prognosis in BC.Methods: A systematic literature search was performed to review eligible studies and clarify the relationship between P-cadherin overexpression and overall survival (OS), disease-free survival (DFS), pathological features, molecular subtypes and molecular phenotypes in BC.Results: Thirty-one studies including 12 332 patients were included. P-cadherin overexpression was correlated with significantly worse OS (HR=1.77, p<0.00001) than P-cadherin-negative. P-cadherin overexpression could lead to high histological grade (OR=3.33, p<0.00001) and lymph node metastasis (OR=1.62, p<0.00001). Moreover, P-cadherin overexpression was associated with low odds of the luminal A subtype and high odds of the human epidermal growth factor receptor-2 (HER2)-positive and triple-negative subtypes. P-cadherin expression led to low expression of oestrogen and progesterone receptor (OR=0.37 and OR=0.36, respectively, both p<0.00001) and high expression of HER2 (OR=2.31, p<0.00001), Ki-67 (OR=2.79, p<0.00001), epidermal growth factor receptor (OR=5.85, p<0.00001) and cytokeratin 5/6 (OR=6.79, p<0.00001).Conclusions: P-cadherin was found to be associated with invasiveness and metastasis. P-cadherin expression can probably be a useful biomarker for predicting poor survival and may act as an independent prognostic predictor.
- 17 September 2020
- Published by BMJ in BMJ Supportive & Palliative Care
- Vol. 12 (e6) , e1-e13
Open AccessBreast cancer prognosis and P-cadherin expression: systematic review and study-level meta-analysis
Objective: P-cadherin can act both as a tumour suppressor and an oncogene. The clinical prognostic value of P-cadherin overexpression in breast cancer (BC) remains unclear. We conducted a study-level meta-analysis to determine whether P-cadherin expression can help predict prognosis in BC.Methods: A systematic literature search was performed to review eligible studies and clarify the relationship between P-cadherin overexpression and overall survival (OS), disease-free survival (DFS), pathological features, molecular subtypes and molecular phenotypes in BC.Results: Thirty-one studies including 12 332 patients were included. P-cadherin overexpression was correlated with significantly worse OS (HR=1.77, p<0.00001) than P-cadherin-negative. P-cadherin overexpression could lead to high histological grade (OR=3.33, p<0.00001) and lymph node metastasis (OR=1.62, p<0.00001). Moreover, P-cadherin overexpression was associated with low odds of the luminal A subtype and high odds of the human epidermal growth factor receptor-2 (HER2)-positive and triple-negative subtypes. P-cadherin expression led to low expression of oestrogen and progesterone receptor (OR=0.37 and OR=0.36, respectively, both p<0.00001) and high expression of HER2 (OR=2.31, p<0.00001), Ki-67 (OR=2.79, p<0.00001), epidermal growth factor receptor (OR=5.85, p<0.00001) and cytokeratin 5/6 (OR=6.79, p<0.00001).Conclusions: P-cadherin was found to be associated with invasiveness and metastasis. P-cadherin expression can probably be a useful biomarker for predicting poor survival and may act as an independent prognostic predictor.
- Open Access
- 29 July 2018
- Published by Wiley in Journal of Immunology Research
- Vol. 2018, 1
Corrigendum to “New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy”
[This corrects the article DOI: 10.1155/2016/9720912.].
- 29 July 2018
- Published by Wiley in Journal of Immunology Research
- Vol. 2018, 1
Open AccessCorrigendum to “New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy”
[This corrects the article DOI: 10.1155/2016/9720912.].
- Open Access
- 1 January 2018
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2018 (1) , 7362340
Cinobufacini Injection Improves the Efficacy of Chemotherapy on Advanced Stage Gastric Cancer: A Systemic Review and Meta‐Analysis
Gastric cancer has a high morbidity and mortality. Chemotherapy regimens are routine advanced stage gastric cancer (AGC) treatment protocols, but most of these drugs have side‐effects such as myelosuppression and gastrointestinal disorders. Cinobufacini, an extractive from TCM, could suppress cell proliferation and inhibit gastric cancer. In this study, we comprehensively reviewed the literature on the efficacy comparison between Cinobufacini injection combined with chemotherapy and chemotherapy solely used in AGC treatment. We extracted data for from six electronic databases to evaluate the efficacy of Cinobufacini injection on AGC patients. Twelve studies with a total of 853 patients were finally included in our study. The results indicated that Cinobufacini injection could increase response rate and disease control rate of chemotherapy on AGC, improve the life quality of AGC patients, increase leukocytes, improve anemia, improve hand‐foot syndrome induced by chemotherapy, and relieve cancer pain. This study has its own limitations that prevented us from drawing a definite conclusion and more well‐designed clinical trials of TCM are needed.
- 1 January 2018
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2018 (1) , 7362340
Open AccessCinobufacini Injection Improves the Efficacy of Chemotherapy on Advanced Stage Gastric Cancer: A Systemic Review and Meta‐Analysis
Gastric cancer has a high morbidity and mortality. Chemotherapy regimens are routine advanced stage gastric cancer (AGC) treatment protocols, but most of these drugs have side‐effects such as myelosuppression and gastrointestinal disorders. Cinobufacini, an extractive from TCM, could suppress cell proliferation and inhibit gastric cancer. In this study, we comprehensively reviewed the literature on the efficacy comparison between Cinobufacini injection combined with chemotherapy and chemotherapy solely used in AGC treatment. We extracted data for from six electronic databases to evaluate the efficacy of Cinobufacini injection on AGC patients. Twelve studies with a total of 853 patients were finally included in our study. The results indicated that Cinobufacini injection could increase response rate and disease control rate of chemotherapy on AGC, improve the life quality of AGC patients, increase leukocytes, improve anemia, improve hand‐foot syndrome induced by chemotherapy, and relieve cancer pain. This study has its own limitations that prevented us from drawing a definite conclusion and more well‐designed clinical trials of TCM are needed.
- Open Access
- 30 December 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (12) , e0168408
Tat-Interacting Protein 30 (TIP30) Expression Serves as a New Biomarker for Tumor Prognosis: A Systematic Review and Meta-Analysis
Tat-interacting protein 30 (TIP30) is a tumor suppressor protein that has been found to be expressed in a wide variety of tumor tissues. TIP30 is involved in the control of cell apoptosis, growth, metastasis, angiogenesis, DNA repair, and tumor cell metabolism. The methylation of the TIP30 promoter is also associated with tumor prognosis. To evaluate this topic further, we conducted a systematic meta-analysis to explore the clinicopathological and prognostic significance of TIP30 for tumor patients. We searched PubMed and EMBASE for eligible studies. We manually searched for printed journals and relevant textbooks. Subgroup analyses were performed based on the region, manuscript quality, methods of vasculogenic mimicry identification, pathology, and number of patients. Fourteen studies with 1705 patients were included in this meta-analysis. A significant association was observed between high expression of TIP30 in patients with cancer with a good overall survival (hazard ratio = 0.53, 95% confidence interval: 0.41–0.69), and good recurrence-free survival or disease free survival (hazard ratio = 0.49, 95% confidence interval: 0.37–0.66). Lack of expression of TIP30 had an association with lymph node metastasis (odds ratio = 3.90, 95% confidence interval: 2.21–6.89) and high tumor node metastasis clinical stage (odds ratio = 2.10, 95% confidence interval: 1.68–2.62). The methylation of the TIP30 promoter did not significantly influence the overall survival (hazard ratio = 0.99, 95% confidence interval: 0.88–1.13) or disease free survival (hazard ratio = 0.62, 95% confidence interval: 0.19–2.02). TIP30 expression is associated with a good prognosis in patients with tumors. Clinical studies with large samples are needed worldwide and standardized protocols should be adopted in the future to achieve a better understanding of the relationship between tumor prognosis and TIP30.
- 30 December 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (12) , e0168408
Open AccessTat-Interacting Protein 30 (TIP30) Expression Serves as a New Biomarker for Tumor Prognosis: A Systematic Review and Meta-Analysis
Tat-interacting protein 30 (TIP30) is a tumor suppressor protein that has been found to be expressed in a wide variety of tumor tissues. TIP30 is involved in the control of cell apoptosis, growth, metastasis, angiogenesis, DNA repair, and tumor cell metabolism. The methylation of the TIP30 promoter is also associated with tumor prognosis. To evaluate this topic further, we conducted a systematic meta-analysis to explore the clinicopathological and prognostic significance of TIP30 for tumor patients. We searched PubMed and EMBASE for eligible studies. We manually searched for printed journals and relevant textbooks. Subgroup analyses were performed based on the region, manuscript quality, methods of vasculogenic mimicry identification, pathology, and number of patients. Fourteen studies with 1705 patients were included in this meta-analysis. A significant association was observed between high expression of TIP30 in patients with cancer with a good overall survival (hazard ratio = 0.53, 95% confidence interval: 0.41–0.69), and good recurrence-free survival or disease free survival (hazard ratio = 0.49, 95% confidence interval: 0.37–0.66). Lack of expression of TIP30 had an association with lymph node metastasis (odds ratio = 3.90, 95% confidence interval: 2.21–6.89) and high tumor node metastasis clinical stage (odds ratio = 2.10, 95% confidence interval: 1.68–2.62). The methylation of the TIP30 promoter did not significantly influence the overall survival (hazard ratio = 0.99, 95% confidence interval: 0.88–1.13) or disease free survival (hazard ratio = 0.62, 95% confidence interval: 0.19–2.02). TIP30 expression is associated with a good prognosis in patients with tumors. Clinical studies with large samples are needed worldwide and standardized protocols should be adopted in the future to achieve a better understanding of the relationship between tumor prognosis and TIP30.